All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-11-01T17:06:36.000Z

FDA grants priority review to tisagenlecleucel for relapsed/refractory follicular lymphoma

Nov 1, 2021
Share:

Bookmark this article

On October 27, 2021, Novartis announced that the U.S. Food and Drug Administration (FDA) had accepted a supplemental biologics license application (sBLA) and granted priority review to tisagenlecleucel, a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received two prior lines of therapy. The European Medicines Agency (EMA) had also accepted Type II variation in the same patient population following orphan drug designation granted from the European Commission. If approved, this will be the third indication for tisagenlecleucel, a treatment option for patients with FL who relapse after standard therapies.1,2

The FDA granted regenerative medicine advanced therapy (RMAT) designation to tisagenlecleucel for R/R FL in April 2020.

This priority review was granted based on positive data from the phase II ELARA trial (NCT03568461), a single-arm, multicenter study evaluating the efficacy and safety of tisagenlecleucel in patients with R/R FL. Updated results from the trial were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and reported on the Lymphoma Hub. ELARA enrolled 98 patients, and 97 patients received tisagenlecleucel. 94 were evaluable for efficacy; 79% of patients maintained a response ≥6 months, and among patients with a partial response (PR), 39% converted to a complete response (CR). At a median follow-up of 10.9 months, median progression-free survival (PFS), overall survival (OS), and duration of response (DoR) were not reached; the 6-month PFS was 76%. Any grade neurological adverse events (AEs) occurred in 9.3% of patients (1.0% Grade 3 or higher), and 48.5% of patients experienced any grade cytokine release syndrome (CRS); there were no reported Grade 3 or higher CRS events.3

Tisagenlecleucel is currently approved by the FDA, EMA, and other regulatory authorities for the treatment of R/R B-cell precursor acute lymphoblastic leukemia (B-ALL) in patients up to 25 years of age, and for the treatment of R/R diffuse large B-cell lymphoma (DLBCL) in adult patients after two or more lines of systemic therapy.4,5

  1. com. Tisagenlecleucel granted FDA priority review for relapsed/refractory follicular lymphoma. https://www.cancernetwork.com/view/tisagenlecleucel-granted-fda-priority-review-for-relapsed-refractory-follicular-lymphoma. Published October 28, 2021. Accessed October 28, 2021.
  2. com. Novartis receives priority review by US FDA and filing acceptance by EMA for Kymriah® to treat patients with relapsed or refractory follicular lymphoma. https://www.novartis.com/news/media-releases/novartis-receives-priority-review-us-fda-and-filing-acceptance-ema-kymriah-treat-patients-relapsed-or-refractory-follicular-lymphoma. Published October 27, 2021. Accessed October 28, 2021.
  3. Schuster SJ, Dickinson MJ, Dreyling MH, et al. Efficacy and safety of tisagenlecleucel (tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (R/R FL): Primary analysis of the phase 2 ELARA trial. J Clin Oncol. 2021;39(15_suppl):7508-7508. DOI: 10.1200/JCO.2021.39.15_suppl.7508.
  4. Kymriah (tisagenlecleucel) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2021.
  5. Kymriah (tisagenlecleucel) [SmPC]. https://www.ema.europa.eu/en/documents/product-information/kymriah-epar-product-information_en.pdf. Updated October 11, 2021. Accessed October 28, 2021.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox